M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,742 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,201 of 1,595 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,692 total, page 46 of 54
Ambulatory Cancer Pain Management: A Feasibility Study
NCT00507351
PR1 Vaccination in Myelodysplastic Syndrome (MDS)
NCT00893997
Data Collection of Demographics and Perioperative Care of Patients Undergoing Laparoscopic Surgery
NCT00490126
Gene Polymorphisms and Symptoms in Lung Cancer Patients
NCT00504374
Sample Collection From Melanoma Patients
NCT00507325
MATCh Parents' Supplemental Survey
NCT00487357
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
NCT00469209
Preop Chemoradiation Resectable Pancreas
NCT00336648
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin
NCT00507585
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
NCT00493467
Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies
NCT00476229
Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients
NCT00513357
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
NCT00492141
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00495040
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00533585
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
NCT00402558
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
NCT00507247
FTS Study in Patients With Advanced Hematologic Malignancies
NCT00867230
Prospective Measurement of Post-Treatment Lymphedema
NCT00495950
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
NCT00514540
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
NCT00330564
Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
NCT00495170
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
NCT00301028
Children's Resiliency, Adjustment, and Coping
NCT00489632
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
NCT00317720
RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies
NCT00508807
Experience of Brain Tumor Caregivers
NCT00352820
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
NCT00493454
Effects of Yoga in Breast Cancer Patients
NCT00508794
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
NCT00299156
Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection
NCT00508170
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
NCT00299182
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
NCT00412243
Endothelial Dysfunction As A Predictor Of Perioperative Outcome
NCT00384683
An Exploratory Study on Optical Assessment of Oral Mucositis
NCT00488332
Active Surveillance in Prostate Cancer
NCT00490763
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
NCT00527657
Experience of Having Chronic Graft-Versus-Host Disease
NCT00353106
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
NCT00294632
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
NCT00515788
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
NCT00305643
Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors
NCT00488644
Effects of Cancer Symptoms on Caregivers
NCT00351988
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
NCT00475020
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
NCT00352846
Use of Spinal Sealant System During Spinal Surgery
NCT00458354
2 Arm Study of Clofarabine IV in MDS Patients
NCT00422032
Phase II Study of ZD6474 in Advanced NSCLC
NCT00290537
Collection of Outcomes Data for Pregnant Patients With Cancer
NCT00507572
Pharmacogenetics, Emotional Reactivity and Smoking
NCT00507728
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
M.D. Anderson Cancer Center: open-pipeline peers nationwide
Peers matched on 2,692 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
M.D. Anderson Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,692 trials (± recruiting share)
- Mayo Clinic · 2,844 trials · 19% recruiting
- National Cancer Institute (NCI) · 3,257 trials · 10% recruiting
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
Sponsors near 20% open enrollment (± trial volume)
- The University of Texas Health Science Center at San Antonio · 20% recruiting · 378 trials
- University of Georgia · 20% recruiting · 59 trials
- University of Houston · 20% recruiting · 64 trials
- Florida International University · 20% recruiting · 89 trials
Related
What to do with this M.D. Anderson Cancer Center page
2,692 registered trials is a research-attention snapshot, not an endorsement of M.D. Anderson Cancer Center or any single study.
- 549 of M.D. Anderson Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hematopoietic and Lymphoid Cell Neoplasm is the condition M.D. Anderson Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hematopoietic and Lymphoid Cell Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. M.D. Anderson Cancer Center pipeline card: 2,692 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.